00:27 , Jul 11, 2019 |  BC Extra  |  Company News

July 10 Company Quick Takes: I-Mab licenses MacroGenics mAb; plus Mirati-Novartis, Jazz-Redx, Sanofi, Horizon and more

I-Mab gains China rights to enoblituzumab I-Mab Biopharma (Shanghai, China) gained exclusive rights to enoblituzumab from MacroGenics Inc. (NASDAQ:MGNX) in China, Hong Kong, Macao and Taiwan for $15 million up front. MacroGenics is eligible for...
12:57 , Apr 30, 2019 |  BC Innovations  |  Distillery Therapeutics

The Parkinson's drug Comtam for obesity and diabetes

DISEASE CATEGORY: Endocrine/metabolic INDICATION: Obesity; diabetes In silico and mouse studies identified Comtan entacapone as an FTO inhibitor that could help treat obesity and diabetes. An in silico screen of FDA-approved drugs for FTO binding...
16:57 , Jan 12, 2018 |  BC Week In Review  |  Company News

Fosun gets Chinese rights to Bial's PD drug

Bial-Portela & Ca. S.A. (S. Mamede do Coronado, Portugal) granted the Jiangsu Wanbang Biopharmaceutical Group Co. Ltd. subsidiary of Shanghai Fosun Pharmaceutical Group Co. Ltd. (Shanghai:600196; HKSE:2196) exclusive, Chinese commercialization rights to Parkinson's disease drug...
18:59 , Dec 8, 2017 |  BC Week In Review  |  Clinical News

Fennec's Pedmark meets in Phase III to prevent hearing loss associated with platinum-based chemotherapies

In October, Fennec Pharmaceuticals Inc. (TSX:FRX; NASDAQ:FENC) reported top-line data from the Phase III SIOPEL 6 trial in 99 children receiving platinum-based chemotherapies showing that Pedmark (STS, sodium thiosulfate) met the primary endpoint of reducing...
20:14 , Feb 16, 2017 |  BC Week In Review  |  Company News

Bial-Portela, Neurocrine Biosciences deal

Bial-Portela granted Neurocrine Biosciences exclusive, North American rights to Parkinson's disease drug Ongentys opicapone (ONO-2370). Bial-Portela will receive $30 million up front and is eligible for up to $115 million in milestones, plus 37% of...
22:24 , Feb 10, 2017 |  BC Extra  |  Company News

Neurocrine gets rights to Bial-Portela's PD drug

Bial-Portela & Ca. S.A. (S. Mamede do Coronado, Portugal) granted Neurocrine Biosciences Inc. (NASDAQ:NBIX) exclusive, North American rights to Parkinson's disease drug Ongentys opicapone (ONO-2370). Bial-Portela will receive $30 million up front and is eligible...
23:12 , Nov 2, 2016 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Parkinson’s disease (PD) In vitro studies identified a pyrazole-based COMT inhibitor that could help treat PD. Fragment-based screening, chemical synthesis and testing in an in vitro assay of mutant and wild-type COMT binding of...
07:00 , Jul 18, 2016 |  BC Week In Review  |  Clinical News

Ongentys opicapone regulatory update

The European Commission approved Ongentys opicapone from Bial-Portela as an adjunctive therapy to levodopa/ dopa decarboxylase (DDC; AADC) inhibitors in adults with Parkinson’s disease (PD) and end-of-dose motor fluctuations who cannot be stabilized on those...
07:00 , May 19, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Catechol-O-methyl-transferase (COMT)

Neurology INDICATION: Parkinson's disease (PD) In vitro studies identified a thiazolidinedione-based COMT inhibitor that could help treat PD. Directed structure-based drug design and in vitro testing identified a thiazolidinedione analog that inhibited the activity of...
07:00 , May 9, 2016 |  BC Week In Review  |  Clinical News

Ongentys opicapone regulatory update

EMA’s CHMP recommended approval of Ongentys opicapone from Bial-Portela as an adjunctive therapy to levodopa/ dopa decarboxylase (DDC; AADC) inhibitors in adults with Parkinson’s disease (PD) and end-of-dose motor fluctuations who cannot be stabilized on...